Matinas BioPharma Holdings, Inc.
MTNB · XNYSCIK 1582554fmd_07TD1JWK2EM6XN6MZWP68K1Y0VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 54 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | – | – |
| Realized investment gains (losses) | 1 | 1 | – | 1 | 1 | 1 | 3 | 0 | – | – |
| Research and development | 4 | 9 | 7 | 11 | 14 | 15 | 17 | 14 | 11 | 0 |
| Total operating expenses | 8 | – | – | – | – | – | – | – | – | – |
| Operating income | (8) | (17) | (15) | (19) | (24) | (25) | (25) | (24) | (25) | (7) |
| Other non-operating income (expense) | (0) | 0 | 0 | 1 | – | 0 | 0 | 0 | 0 | (0) |
| Income before taxes | – | – | – | – | – | – | – | (23) | (24) | (10) |
| Income tax expense | – | 0 | 1 | – | – | – | – | – | (0) | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (24) | – |
| Net income | (8) | (15) | (14) | (17) | (22) | (23) | (21) | (23) | (24) | (10) |
| Net income to common shareholders | (12) | (33) | (15) | (18) | (23) | (24) | (21) | – | (24) | (11) |